A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and Mesoblast Limited from 2014 to 2023. Corcept Therapeutics, known for its innovative treatments, has seen a steady increase in SG&A expenses, rising from approximately $35 million in 2014 to $184 million in 2023. This represents a growth of over 400%, reflecting the company's expansion and increased market activities.

Conversely, Mesoblast Limited, a leader in regenerative medicine, experienced fluctuations in its SG&A expenses. Starting at around $54 million in 2014, the expenses peaked at $65 million in 2015, before stabilizing around $53 million in 2023. This trend indicates a more conservative approach to operational spending. Notably, data for 2024 is missing, suggesting potential changes in reporting or financial strategy.